- Home
- TNGX vs SPOK Comparison
TNGX vs SPOK Comparison
Compare TNGX & SPOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- SPOK
- Stock Information
- Founded
- TNGX 2014
- SPOK 2004
- Country
- TNGX United States
- SPOK United States
- Employees
- TNGX N/A
- SPOK N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- SPOK Telecommunications Equipment
- Sector
- TNGX Health Care
- SPOK Telecommunications
- Exchange
- TNGX Nasdaq
- SPOK Nasdaq
- Market Cap
- TNGX 317.4M
- SPOK N/A
- IPO Year
- TNGX N/A
- SPOK 1992
- Fundamental
- Price
- TNGX $1.76
- SPOK $15.89
- Analyst Decision
- TNGX Strong Buy
- SPOK Hold
- Analyst Count
- TNGX 7
- SPOK 1
- Target Price
- TNGX $12.33
- SPOK $15.00
- AVG Volume (30 Days)
- TNGX 801.9K
- SPOK 155.3K
- Earning Date
- TNGX 05-07-2025
- SPOK 04-30-2025
- Dividend Yield
- TNGX N/A
- SPOK 7.85%
- EPS Growth
- TNGX N/A
- SPOK N/A
- EPS
- TNGX N/A
- SPOK 0.73
- Revenue
- TNGX $42,069,000.00
- SPOK $137,653,000.00
- Revenue This Year
- TNGX N/A
- SPOK $3.51
- Revenue Next Year
- TNGX N/A
- SPOK N/A
- P/E Ratio
- TNGX N/A
- SPOK $21.82
- Revenue Growth
- TNGX 15.17
- SPOK N/A
- 52 Week Low
- TNGX $1.71
- SPOK $13.24
- 52 Week High
- TNGX $12.02
- SPOK $17.96
- Technical
- Relative Strength Index (RSI)
- TNGX 33.97
- SPOK 40.62
- Support Level
- TNGX $1.80
- SPOK $15.70
- Resistance Level
- TNGX $2.04
- SPOK $16.86
- Average True Range (ATR)
- TNGX 0.18
- SPOK 0.38
- MACD
- TNGX 0.01
- SPOK -0.07
- Stochastic Oscillator
- TNGX 20.19
- SPOK 27.61
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.